--128 enrolled participants, as of December 31, 2024, exceeds initial target of 90 participants-- --150 maximum participant enrollment projected by…
Collaboration delivers strategic Neurodiversity initiatives, with comprehensive support and advanced analytics and insights tailored to both individual and organizational needs.…
Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription…
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a…
RESTON, Va., Jan. 6, 2025 /PRNewswire/ -- Leidos (NYSE:LDOS) today announced that its wholly owned subsidiary, QTC Medical Services, operating under the…
MIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”),…
VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio…
Leland to discuss his best-selling book, “The Country of the Blind: A Memoir at the End of Sight” LOS ANGELES,…
Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the…